https://doi.org/10.55788/bd816921
Dr Koianka Trencheva (Weill Cornell Medicine, NY, USA) and her research team aimed to compare Kono-S and side-to-side anastomosis following ileocecectomy for Crohn’s terminal ileitis [1]. In a multicentre trial (NCT03256240), 288 patients were randomised 1:1 to one of these interventions. The endoscopic recurrence rate at 3–6 months post-surgery was the main outcome measure.
The 3–6-month endoscopic recurrence rates were 25.9% and 27.8% in the Kono-S arm and side-to-side arm, respectively (P=0.78). “We noticed that the length of the surgical procedure was approximately 20 minutes longer in the Kono-S arm (mean 154 vs 132 minutes; P=0.39),” added Dr Trencheva. Furthermore, post-op complication rates and anastomotic stricture rates (3.0% vs 2.6%; P=1.00) were comparable for both arms.
“At 3–6 months follow-up, Kono-S and side-to-side anastomosis yield similar outcomes for patients undergoing ileocecectomy for Crohn’s terminal ileitis,” concluded Dr Trencheva.
- Trencheva K, et al. Postoperative endoscopic recurrence after resection of Crohn’s terminal ileitis with Kono-S or side-to-side functional end anastomosis: results of a multicenter prospective randomized trial. OP20, 19th Congress of ECCO, 21–24 February 2024, Stockholm, Sweden.
Copyright ©2024 Medicom Medical Publishers
Posted on
Previous Article
« Risk factors for re-resection in Crohn’s disease revealed Next Article
Extended mesenterectomy or mesenteric-sparing surgery in Crohn’s disease? »
« Risk factors for re-resection in Crohn’s disease revealed Next Article
Extended mesenterectomy or mesenteric-sparing surgery in Crohn’s disease? »
Table of Contents: ECCO 2024
Featured articles
Meet the Trialist: Dr Yasuharu Maeda on AI-assisted endoscopy
IL-23 Inhibitors on the Rise
VIVID-1: Mirikizumab meets expectations in Crohn’s disease
COMMAND: Long-term efficacy benefits of risankizumab in ulcerative colitis
SEQUENCE: Risankizumab versus ustekinumab across endpoints
QUASAR: Guselkumab improves QoL for patients with ulcerative colitis
Fatigue, urgency, and QoL improvements on mirikizumab in Crohn’s disease
Inspiring Drug Trials and Treatment Strategies
Novel agent VTX002 holds promise in ulcerative colitis
PROFILE: Top-down treatment strategy benefits patients with early Crohn’s disease
Biologicals and JAK inhibitors hold promise in microscopic colitis
Ustekinumab as alternative for anti-TNFs in HLA-DQA1*05-positive Crohn’s disease
How effective is dose escalation of biologicals in IBD?
Make Way for JAK Inhibitors
Promising data for JAK inhibitors in Crohn’s disease from phase 2 trial
U-ENDURE long-term extension: sustained efficacy of upadacitinib in Crohn’s disease
TRIUMPH: Tofacitinib as rescue option for acute severe ulcerative colitis
Focus on Endoscopy, Screening, and Risk Factors
Should we screen for metabolic bone disease at IBD diagnosis?
Predicting relapse in ulcerative colitis with AI-assisted endoscopy
Clear case for NUDT15 genetic testing in Asian patients with IBD
HELIOS: HD-WLE can yield similar neoplasia detection rates as HD-CE
CURE-CD: Capsule endoscopy-guided proactive treatment leads to fewer relapses in Crohn’s disease
Sharp Surgical Solutions
Extended mesenterectomy or mesenteric-sparing surgery in Crohn’s disease?
Similar outcomes for Kono-S and side-to-side anastomosis in Crohn’s terminal ileitis
Risk factors for re-resection in Crohn’s disease revealed
ADMIRE-CD-II: Darvadstrocel does not meet primary endpoint in complex peri-anal fistula
Related Articles
© 2024 Medicom Medical Publishers. All rights reserved. Terms and Conditions | Privacy Policy
HEAD OFFICE
Laarderhoogtweg 25
1101 EB Amsterdam
The Netherlands
T: +31 85 4012 560
E: publishers@medicom-publishers.com